Hernán Trimarchi

Hospital Británico — UY

Medicine · Health Sciences

31h-index5.3kcitations215works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal Diseases and Glomerulopathies(98), Chronic Kidney Disease and Diabetes(41), Dialysis and Renal Disease Management(22), Platelet Disorders and Treatments(22), Lysosomal Storage Disorders Research(20)

Publications210 total

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
New England Journal of Medicine·2025· 9 cited
Iptacopan in Patients With IgA Nephropathy From East Asia
Kidney International Reports·2025Open Access
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
New England Journal of Medicine·2025· 11 cited
Consenso latinoamericano de síndrome hemolítico urémico atípico
Nefrología Latinoamericana·2025Open Access
DMX-200 in Patients With Primary Focal Segmental Glomerulosclerosis: Results of the Phase 2 ACTION2 Trial
Kidney International Reports·2025· 1 citedOpen Access
#2651 Sustainability and depth of UPCR reduction in patients with primary IgAN treated with nefecon: a secondary analysis of the Phase 3 NefIgArd trial
Nephrology Dialysis Transplantation·2025Open Access
#3251 Nefecon provides kidney benefit irrespective of time since diagnosis in patients with IgAN: a subanalysis of the NefIgArd study
Nephrology Dialysis Transplantation·2025Open Access
#3302 SEARCH project: early diagnosis of chronic kidney disease in Argentina. Initial results
Nephrology Dialysis Transplantation·2025Open Access
#2936 Origin 3 study design: a global, randomized, controlled, Phase 3 study of atacicept in IgA nephropathy
Nephrology Dialysis Transplantation·2025
ORIGIN 3: A Phase 3 Trial of Atacicept in IgAN
Journal of the American Society of Nephrology·2025
#2444 Patients with focal segmental glomerulosclerosis (FSGS) achieved low proteinuria targets earlier and more often with sparsentan (SPAR) vs irbesartan (IRB) in DUPLEX
Nephrology Dialysis Transplantation·2025Open Access
#2626 Effect of iptacopan discontinuation on proteinuria and complement biomarkers in patients with immunoglobulin A nephropathy (IgAN): a post hoc analysis from a Phase II trial
Nephrology Dialysis Transplantation·2025Open Access
Sibeprenlimab for the Treatment of IgAN: VISIONARY Phase 3 Interim and Prespecified Subgroup Analyses
Journal of the American Society of Nephrology·2025
Biomarker Insights from the Phase 3 APPLAUSE-IgAN Study: Iptacopan's Proteomic Signature in IgAN
Journal of the American Society of Nephrology·2025
#3345 Nefecon provides kidney benefit irrespective of baseline eGFR in patients with IgAN: a subanalysis of the NefIgArd study
Nephrology Dialysis Transplantation·2025Open Access
Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
Kidney International·2025· 12 cited
Core Outcome Measure for Life Participation in Patients with CKD
Clinical Journal of the American Society of Nephrology·2025
Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]
Kidney International Reports·2025Open Access
WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY
Kidney International Reports·2025· 2 citedOpen Access
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts
Kidney International Reports·2025· 1 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

Jonathan Barratt(17), Brad H. Rovin(12), Mariano Forrester(12), Fernando Lombi(10), Vanesa Pomeranz(10), Hong Zhang(8), Vlado Perkovic(8), Romina Iriarte(8), Alexis Muryan(8), Bart Maes(7), Rosanna Coppo(6), Charles E. Alpers(6), Vladimı́r Tesař(6), Emilio Freixas(6), Romina Canzonieri(6), Amalia Schiel(6), Pablo Young(6), Jürgen Floege(5), Jai Radhakrishnan(5), Michelle N. Rheault(5)